ProCE Banner Activity

CME

Evolving Clinical Considerations for Breast Cancer Brain Metastases: Expert Case Discussions

Watch this on-demand Webcast of a live CCO Webinar featuring the latest information and insights from 2 experts on the current optimal management of patients with breast cancer and brain metastases.

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits

Released: January 22, 2021

Expiration: January 21, 2022

No longer available for credit.

Share

Faculty

Ruth M. O’Regan

Ruth M. O’Regan, MD

Associate Professor, Hematology and Oncology, Medical Oncology
Director of Translational Breast Cancer Research
Winship Cancer Institute
Emory University
Atlanta, Georgia

Lee Schwartzberg

Lee Schwartzberg, MD

Professor of Medicine
Chief
Division of Hematology and Oncology
University of Tennessee Health Science Center
Memphis, Tennessee
Executive Director
West Cancer Center
Germantown, Tennessee

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Genentech, a member of the Roche Group

Puma Biotechnology, Inc.

Target Audience

This program is intended for oncologists and other clinicians involved in the management of metastatic breast cancer patients with CNS metastases.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Discuss the risk factors associated with CNS metastases in patients with breast cancer
  • Evaluate available and emerging clinical data on the use of systemic therapies to treat breast cancer brain metastases
  • Incorporate expert consensus and guideline recommendations into practice taking a multidisciplinary team approach to treatment
  • Integrate new therapeutic approaches into clinical practice for patients with brain metastases from breast cancer based on individual patient and tumor characteristics

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty Disclosure

Primary Author

Ruth M. O’Regan, MD

Associate Professor, Hematology and Oncology, Medical Oncology
Director of Translational Breast Cancer Research
Winship Cancer Institute
Emory University
Atlanta, Georgia

Lee Schwartzberg, MD

Professor of Medicine
Chief
Division of Hematology and Oncology
University of Tennessee Health Science Center
Memphis, Tennessee
Executive Director
West Cancer Center
Germantown, Tennessee

Lee Schwartzberg, MD, FACP, has disclosed that he has received funds for research support from Amgen and consulting fees from Amgen, AstraZeneca, Bristol-Myers Squibb, Genentech/Roche, Genomic Health, Helsinn, Myriad, Napo, Pfizer, and Spectrum and other financial support from Bayer.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael Andrie, PhD, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 22, 2021, through January 21, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the competence and performance of learners to apply practice-changing clinical data and expert recommendations regarding the treatment of patients with metastatic breast cancer and CNS metastases.